|
Compounder’s Growth Plans Failed to Elicit FDA Clamp Down
Congressional investigators have compiled a history of inspections at the New England Compounding Center (NECC) in Framingham, Mass., that shows regulators considered placing the compounding pharmacy under tighter control, but did not.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives